Pharma & Biotech Global Week in Review 1 July 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Highlights this week included:

US: White House recommends 7-year data exclusivity period for follow-on biologics – HR 1427, S726, HR 1548 (Patent Docs) (Patent Baristas) (IP Watchdog) (Holman’s Biotech IP Blog) (Holman’s Biotech IP Blog) (Patent Docs) (GenericsWeb)

US: Sen Nelson introduces S 1315 bill to amend ANDA ‘first applicant’ definition that would effectively gut 180-day exclusivity (FDA Law Blog) (Patent Baristas)

General

WHO or who should guarantee the right to health? – International experts debate how human rights could be infused into global health strategies (Intellectual Property Watch)

Reverse payments: (how) do they affect SPCs? (The SPC Blog)

EU: Germany refers question to ECJ concerning SPCs for plant protection products (The SPC Blog)

EU: Nutritional supplements: is Class 5 their natural home? OHIM decision in Laboratorios Andrómaco, S.A. v OTC Pharma International B V (Class 46)

India: Valgancyclovir hearings and the need for more transparency: Roche v Cipla (Spicy IP)

Japan approves first follow-on biologic (Patent Docs)

UK: Journal of Intellectual Property Law & Practice note on ‘Paediatric extensions: the requirement of a compliance statement’ on UK IPO decision in Merck and Co, Inc (The SPC Blog)

US: Sen Nelson introduces s 1315 bill to amend ANDA ‘first applicant’ definition that would effectively gut 180-day exclusivity (FDA Law Blog) (Patent Baristas)

US: Federal Trade Commission reports: authorised generics, during the 180-day exclusivity period, benefit consumers and the American healthcare system (GenericsWeb)

US: FTC Chairman Jon Leibowitz says ‘stopping collusive ‘pay-for-delay’ settlements between brand and generic pharmaceutical firms would save consumers $3.5 billion a year’ (FDA Law Blog)

US: White House recommends 7-year data exclusivity period for follow-on biologics – HR 1427, S726, HR 1548 (Patent Docs) (Patent Baristas) (IP Watchdog) (Holman’s Biotech IP Blog) (Holman’s Biotech IP Blog) (Patent Docs) (GenericsWeb)

US: IPO continues to support 14-year exclusivity period for biologics (Patent Docs)

US: Kappos nomination supported by industry and patent groups (Patent Docs)

US: ITC: Nantong Foreign Medicines & Health Co’s motion for summary judgment of invalidity denied in investigation concerning non-shellfish derived glucosamine (ITC 337 Law Blog)

US: CAFC affirms judgment granting defendant/appellee’s motion to dismiss for lack of personal jurisdiction: Autogenonomics v Oxford Gene Technology (Patent Docs) (Global IP Watch)

Venezuela: Is Venezuela the new Thailand? (Patent Docs)

Products

Avapro (Irbesartan) – Spain: Fourth Commercial Court of Barcelona rejects preliminary injunction petition by Sanofi-Aventis and Bristol-Myers Squibb for alleged patent infringement (International Law Office)

Cozaar/Hyzaar (Losartan/Hydrochlorothiazide and Losartan) –US: Teva sues FDA over generic Cozaar and Hyzaar 180-day exclusivity forfeiture and patent delisting rule (The FDA Law Blog)

Eloxatin (Oxaliplatin) – US: District Court of New Jersey finds Teva, Sandoz and Mayne do not infringe Eloxatin patents (The IP Factor)

Humira (Adalimumab) – US: University of Iowa accuses Abbott’s Humira of infringing its patents covering ‘transfering vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence’ (Patent Docs)

Lexapro (Escitalopram) – Australia: FCAFC – clarification of novelty test for enantiomers: H Lundbeck A/S v Alphapharm Pty Ltd (Patent Baristas)

Perforomist (Formoterol fumarate) – US: Dey files patent infringement suit against Teva following Para IV certification as part of ANDA to produce generic Perforomist (Patent Docs)

Vanos (Fluocinonide) – US: Medicis files patent infringement suit against Glenmark following Para IV challenge concerning Vanos (Patent Docs)

Viagra (Sildenafil) – Canada: Federal Judge dismisses Novopharm’s challenge to validity of Viagra patent but raises uncomfortable questions (The IP Factor)

Xyzal (Levocetririzine) – US: Perrigo confirms that its partner Synthon has filed for generic version of Xyzal solution and announcement of lawsuit by Sepracor/UCB (GenericsWeb)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: